Table 1.
Baseline characteristics of the participants.
| Placebo/SAx (n = 33) |
SAx/Placebo (n = 34) |
||
|---|---|---|---|
| Gender | (Female %, n) | 78.79 (26) | 79.41 (27) |
| Age | (years) | 53.21 ± 4.2 | 52.79 ± 4.8 |
| Smoking | (Smokers %, n) | 18.18 (6) | 26.47 (9) |
| Weight | (kg) | 66.26 ± 11.8 | 64.08 ± 10.9 |
| BMI | (kg/m2) | 24.64 ± 2.9 | 24.56 ± 3.2 |
| Waist circumference | (cm) | 80.51 ± 9.2 | 82.58 ± 9.8 |
| FM | (%) | 29.18 ± 6.7 | 28.76 ± 6.4 |
| FFM | (%) | 70.82 ± 6.7 | 71.24 ± 6.4 |
| MM | (%) | 48.03 ± 7.7 | 47.87 ± 5.5 |
| SBP | (mmHg) | 110.3 ± 13.1 | 110.9 ± 12.9 |
| DBP | (mmHg) | 74.06 ± 10.8 | 73.75 ± 9.5 |
| HR | (bpm) | 67.36 ± 8.9 | 70.41 ± 7.5 |
| TC | (mg/dL) | 226.7 ± 29.6 | 224.6 ± 35.4 |
| LDL-C | (mg/dL) | 144.3 ± 23.9 | 145.3 ± 28.6 |
| HDL-C | (mg/dL) | 66.25 ± 12.9 | 62.00 ± 12.6 |
| TG | (mg/dL) | 80.56 ± 24.6 | 86.52 ± 44.0 |
Data presented as means ± standard deviations (SDs). SAx: oral supplementation with hydroxytyrosol (HT) and punicalagin (PC); BMI: body mass index; FM: fat mass; FFM: fat-free mass; MM: muscle mass; SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; and TG: triglycerides. There were no significant differences in the baseline state between the two intervention sequences.